Published by Josh White on 11th January 2024
(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).
URL: http://www.digitallook.com/dl/news/story/34019849/...